Fiona Du Monceau

Executive Vice President Patient Evidence, UCB

Fiona Du Monceau is the Executive Vice President Patient Evidence at UCB. She leads the late-stage clinical development of UCB’s molecules and the strategic and operational teams to build the critical differentiated evidence. This includes regulatory and development, medical affairs, payor and HTA teams and interaction with key external stakeholders such as government regulators, patient organizations and public officials. 

Fiona has extensive experience in the pharmaceutical industry and a proven leadership track record. She served as COO and CFO of ExeVir Bio, leading the company from its spin-out to clinical trials. Fiona also worked for UCB Ventures and held leadership roles at GlaxoSmithKline, McKinsey & Company, and Eli Lilly. 

Fiona was a board member of Financière de Tubize and Medifin and served as a governor of the London Business School. Fiona holds a Master of Science in Management from Solvay Brussels School and a Management and a Master of Business Administration from Harvard Business School. Fiona is a Fulbright Scholar and BAEF scholarship recipient.